Document is current
Any future updates will be listed below
-
Authors
Clark, John A. http://orcid.org/0000-0001-6916-9195
Conway Morris, Andrew http://orcid.org/0000-0002-3211-3216
Curran, Martin D.
White, Deborah http://orcid.org/0000-0002-9254-996X
Daubney, Esther
Kean, Iain R. L. http://orcid.org/0000-0003-1066-8285
Navapurkar, Vilas http://orcid.org/0000-0002-3610-3568
Bartholdson Scott, Josefin http://orcid.org/0000-0003-3380-4446
Maes, Mailis http://orcid.org/0000-0002-0266-6557
Bousfield, Rachel http://orcid.org/0000-0001-7828-4048
Török, M. Estée http://orcid.org/0000-0001-9098-8590
Inwald, David http://orcid.org/0000-0001-9518-7821
Zhang, Zhenguang
Agrawal, Shruti
Kanaris, Constantinos
Khokhar, Fahad http://orcid.org/0000-0001-5959-0680
Gouliouris, Theodore http://orcid.org/0000-0002-2011-1205
Baker, Stephen http://orcid.org/0000-0003-1308-5755
Pathan, Nazima http://orcid.org/0000-0002-9447-4252
-
Funding
Funding for this research was provided by:
Gates Cambridge Trust (OPP1144)
Addenbrooke's Charitable Trust, Cambridge University Hospitals (900240, 900240, 900240, 900240, 900240)
NIHR Cambridge Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 1 November 2022
Accepted: 6 January 2023
First Online: 10 January 2023
Declarations
:
: The study was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Approval was granted by the Yorkshire and Humber-Bradford Leeds Research Ethics Committee (REC ref 20/YH/0089 on 26 March 2020). The trial was registered prior to commencement on ClinicalTrials.gov (NCT04233268).
: MDC is the inventor on a patent held by the Secretary of State for Health (UK government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, director, and shareholder in Cambridge Infection Diagnostics (CID) which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. ACM and SB are members of the Scientific Advisory Board of CID. ACM receives speaking fees from Boston Scientific. All other authors declare no conflict of interest.
